Reviewer’s report

Title: Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control

Version: 0 Date: 29 Dec 2017

Reviewer: Theodoros Androutsakos

Reviewer's report:

Overall a good effort. However it needs to be revised as language is concerned (t.ex. it is not with sustained THE viral response, just sustained viral response) and I think you need to show us some more data about the HCV status of the patients included in this study (viral load and genotype). Moreover you are saying that 44 patients interrupted their treatment due to adverse effects. I would like to know what kind of adverse effects were these. 11 of your patients are said to have stopped treatment due to neuropathy so they should not be included in this study since your patients have HCV related and not interferon related neuropathy. Last but not least looks like 50% of your patients have also HBV infection unless what you mean is they had previous HBV infection, so I would like you to comment on that as well.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Not suitable for publication unless extensively edited

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal